NCT06498622View on ClinicalTrials.gov

Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 20, 2024

Primary Completion Date

May 20, 2027

Study Completion Date

May 20, 2027

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Donafenib + Envafolimab

"Drug: Envafolimab Envafolimab 300mg IH D1 q3w Other Name: Immunotherapy, Anti-PD-L1 antibody~Drug: Donafenib Donafenib 100mg PO bid Other Name: tyrosine kinase inhibitor, TKI"

Trial Locations (2)

230000

RECRUITING

Anhui province hospital, Hefei

236015

RECRUITING

No.2 People's Hospital of Fuyang city, Fuyang

All Listed Sponsors
lead

Anhui Provincial Hospital

OTHER_GOV